UroGen Pharma Ltd.·4

Jul 30, 4:02 PM ET

Schoenberg Mark 4

4 · UroGen Pharma Ltd. · Filed Jul 30, 2025

Insider Transaction Report

Form 4
Period: 2025-07-28
Schoenberg Mark
Chief Medical Officer
Transactions
  • Exercise/Conversion

    Ordinary Shares

    2025-07-28+10,000163,378 total
  • Sale

    Ordinary Shares

    2025-07-28$19.14/sh5,149$98,552158,229 total
Footnotes (3)
  • [F1]Represents the settlement of performance stock units granted on January 31, 2024 that vested upon the achievement of a corporate milestone event.
  • [F2]Each performance stock unit represents a contingent right to receive one ordinary share of the Issuer.
  • [F3]Represents shares sold to satisfy withholding tax obligations upon the settlement of performance stock units.

Documents

1 file
  • 4
    rdgdoc.xmlPrimary

    FORM 4